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INTRODUCTION
Cardiovascular autonomic modulation is altered in 
patients with essential hypertension [1, 2]. Sympathetic 
overdrive, parasympathetic withdrawal and diminished 
baroreflex function are well documented in patients 
with hypertension [3, 4, 5]. Although their precise role 
in the etiopathogenesis of essential hypertension is not 
accurately defined, they have at least contributed to 
the increased risk for cardiovascular morbidity and 
mortality in this cohort of patients. Enhanced sympa-
thetic activity in the early morning hours in patients 
with hypertension is connected with increased cardio-
vascular morbidity and mortality in this period of the 
day [6-10]. Baroreflex sensitivity predicts all-cause 
mortality and a sudden death in hypertensive patients 
with chronic renal failure [11, 12].
Pharmacological effects of any drug given to the 
patient with essential hypertension should be evalu-
ated completely; not only its primary antyhyperten-
sive effect, but also its effects on autonomic cardiovas-
cular function, haemodynamic status and myocardial 
vulnerability. This approach is complex, demanding 
not only one or few tests, but a battery of tests.
Amlodipine is a long-acting dihydropiridine calcium 
channel blocker widely used in antihypertensive treat-
ment. Data concerning the influence of amlodipine on 
autonomic function and haemodynamic parameters 
in patients with essential hypertension are conflicting, 
some stating that amlodipine has little if any effects on 
the autonomic nervous system (ANS), and others that 
it increases sympathetic activity [13, 14, 15]. According 
to the latter, amlodipine even stimulates vagal activity 
[16]. In these studies, the effect of amlodipine on the 
autonomic function was assessed frequently in small 
numbers of patients using incomplete autonomic eval-
uation, with the results often projecting the limitation 
of the employed tests.
OBJECTIVE
The aim of this study was to thoroughly evaluate early 
and long-term effects of amlodipine, on cardiovas-
cular autonomic function, haemodynamic status and 
myocardial vulnerability in patients with mild uncom-
plicated essential hypertension.
SUMMARY
Introduction  Cardiovascular autonomic modulation is altered in patients with essential hypertension.
Objective  To evaluate acute and long-term effects of amlodipine on cardiovascular autonomic function and haemo-
dynamic status in patients with mild essential hypertension.
Methods  Ninety patients (43 male, mean age 52.12 ±10.7) years with mild hypertension were tested before, 30 minutes 
after the first 5 mg oral dose of amlodipine and three weeks after monotherapy with amlodipine. A comprehensive 
study protocol was done including finger blood pressure variability (BPV) and heart rate variability (HRV) beat-to-beat 
analysis with impedance cardiography, ECG with software short-term HRV and nonlinear analysis, 24-hour Holter ECG 
monitoring with QT and HRV analysis, 24-hour blood pressure (BP) monitoring with systolic and diastolic BPV analysis, 
cardiovascular autonomic reflex tests, cold pressure test, mental stress test. The patients were also divided into sympa-
thetic and parasympathetic groups, depending on predominance in short time spectral analysis of sympathovagal 
balance according to low frequency and high frequency values.
Results  We confirmed a significant systolic and diastolic BP reduction, and a reduction of pulse pressure during day, 
night and early morning hours. The reduction of supraventricular and ventricular ectopic beats during the night was 
also achieved with therapy, but without statistical significance. The increment of sympathetic activity in early phase of 
amlodipine therapy was without statistical significance and persistence of sympathetic predominance after a few weeks 
of therapy detected based on the results of short-term spectral HRV analysis. All time domain parameters of long-term 
HRV analysis were decreased and low frequency amongst spectral parameters. Amlodipne reduced baroreflex sensitiv-
ity after three weeks of therapy, but increased it immediately after the administration of the first dose.
Conclusion  The results of the study showed that amlodipine affected autonomic modulation as a shift to sympathetic 
hyperactivity, but without statistical significance. In the selected group of patients with vagal predominance in sympa-
thovagal balance, amlodipine increased sympathetic and decreases vagal activity. Therefore we conclude that amlo-
dipine mostly exerts impact on autonomic function modulation in patients with vagal predominance in resting state.
Keywords:  amlodipine; hypertension; autonomic function; heart rate variability; haemodynamic; baroreflex sensitivity
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METHODS
Study population
In this study 90 patients were enrolled (43 male), mean age 
52.12±10.7 years. The patients were recruited from previ-
ously treated hypertensive patients in whom antihyper-
tensive treatment did not meet therapeutic goals: systolic 
blood pressure (BP) lower than 140 mm Hg and diastolic 
BP lower than 90 mm Hg. In all patients antihypertensive 
drugs were withdrawn and one week placebo pretreatment 
started. The inclusion criteria were prehypertension or hyper-
tension stage one (JNC VII), normal physical examination, 
normal electrocardiography and normal laboratory tests 
(fasting plasma glucose, blood urine nitrogen, serum creat-
inine, liver function tests and serum electrolytes). Exclusion 
criteria were secondary arterial hypertension, renal failure, 
coronary artery disease, diabetes mellitus, autoimmune 
disease or the use of drugs such as neuroleptics, antidepres-
sants, lithium, antiarrhythmics, or cimetidine. All patients 
completed the trial and demonstrated good drug compli-
ance. There were no adverse events observed in this trial.
Study protocol
After one week of pretreatment with placebo, baseline 
evaluation was done and included the evaluation of auto-
nomic function and haemodynamic status (according to 
the three steps protocol performed in our Neurocardiology 
Laboratory), 24-hour ambulatory electrocardiography 
monitoring with heart rate variability (HRV) analysis and 
24-hour ambulatory blood pressure monitoring (ABPM).
After baseline evaluation, we investigated the effects of 
the first 5 mg dose of amlodipine on the autonomic func-
tion and haemodynamic status in all patients, using real 
time beat-to-beat heart rate and BP monitoring and calcu-
lating HRV and blood pressure variability (BPV), as well 
as baroreflex sensitivity (Task Force monitor) [17]. In 10 
patients changes in haemodynamic parameters 30 minutes 
after the first 5 mg dose of amlodipine were determined 
using impedance cardiography (Task Force monitor).
After baseline evaluation and analysis of the effects of the 
first dose, all patients were assigned to receive 5 mg amlo-
dipine once daily for three weeks. Next, amlodipine mono-
therapy, evaluation of autonomic function and haemody-
namic status, as well as 24-hour ambulatory ECG moni-
toring with HRV analysis and 24-hour ABPM were repeated. 
Results were compared with baseline values before amlo-
dipine treatment. The study was approved by the Scientific 
Ethical Committee of Clinical Hospital Center “Bežanijska 
kosa”. All participants gave written informed consent in 
accordance with the declaration of Helsinki.
Evaluation of autonomic function and 
haemodynamic status
All patients were tested in the Neurocardiology Laboratory 
of the Clinical Hospital Centre “Bežanijska kosa” using 
comprehensive three steps protocol for the assessment of 
ANS and haemodynamic status. The three steps protocol 
included: 1) five standard Ewing’s clinical autonomic func-
tion tests, cold pressure and mental stress test, 2) short-
term ECG and short-term HRV analysis, 3) non-invasive 
beat-to-beat monitoring and analysis of haemodynamic 
parameters and autonomic function (Task Force monitor) 
[18, 19]. The patients were tested under conditions of ideal 
room temperature (23°C), without any previous consump-
tion of alcohol, nicotine, or food.
Clinical autonomic function tests
Cardiovascular reflex tests according to Ewing’s battery 
were the first step in our assessment of autonomic func-
tion [20]. The participants rested in supine position for 
10 minutes before starting the tests and also rested for 2 
minutes between each test.
Parasympathetic tests: heart rate response to Valsalva 
manoeuvre, heart rate response to deep breathing, heart 
rate response to standing (ratio 30:15).
Sympathetic tests: BP response to standing, BP response to 
sustained handgrip test, cold pressure test, mental stress test.
The results of cardiovascular reflex tests were expressed 
as a scoring system: normal (0), borderline (1) and abnormal 
(2), related to the normal values from tables according to 
Ewing.
Short-term ECG and short-term heart rate  
variability analysis
The analysis of standard 12 leads ECG recording using a 
commercially available software (Schiller AT-10, Austria) 
included ECG wave and interval analysis: duration of P 
wave, PQ interval, QRS complex, QT and QTc interval.
Short-term HRV analysis was done from 512 consecu-
tive RR intervals using the commercial software (Schiller 
AT-10, Austria) according to previously published guide-
line [21]. Using nonlinear HRV analysis, we compared the 
shape of Poincare plot before and after amlodipine therapy.
Task Force Monitor: beat-to-beat analysis of HRV and 
BPV, baroreflex sensitivity and haemodynamic parameters.
Holter ECG: rhythm analysis, long-term HRV analysis, 
ST segment, QT and QTc analysis, T wave morphology 
analysis.
From time domain HRV analysis, the following time 
domain variables were computed: mean RR interval for 
24 hours (mean NN), standard deviation of normal RR 
intervals (SDNN), standard deviation of all 5-minute mean 
normal RR intervals (SDANN), square root of the mean of 
the sum of the squares of differences between adjacent RR 
intervals (r-MSSD), and percentage of adjacent RR inter-
vals differing >50 ms (pNN50). From frequency domain 
HRV analysis, the following 24-hour frequency domain 
indices were determined: total power (TP; 0-0.4 Hz), high 
frequency power (HF; 0.15-0.4 Hz), low frequency power 
(LF; 0.04-0.15 Hz), and the LF/HF ratio. Heart rate was 
measured in milliseconds (ms); variance, referred to as SERBIAN ARCHIVES OF MEDICINE 373
the power in a portion of the total spectrum of frequen-
cies, was measured in milliseconds squared (ms2). From 
ambulatory ECG recording, beat-to-beat analysis of QT 
and QTc interval was performed [22].
24-hour ambulatory blood pressure monitoring
The evaluation of a 24-hour profile of BP was done using 
a recorder and a commercial software for analysis (Mobil-
O-graph). The monitoring began at approximately 11 a.m. 
and BP measurements were performed by oscillometric 
method every 15 minutes all day long.
Autonomic nervous system adjustment  
(ANSA) method
In order to precisely define the effect of amlodipine on 
sympathovagal balance we hypothesized that the effects 
of the drug depended greatly on the basal state of sympa-
thovagal balance which changed with sympathetic or 
vagal predominance. Having in mind that basal sympa-
thovagal balance differs among patients, in the first 
phase of our study we determined the type of distur-
bance, that is, dominance. According to the recommen-
dations by the European Society of Cardiology and the 
North American Society of Pacing and Electrophysiology, 
a short-term spectral analysis, which enables LF and 
HF values in normalized units to be obtained, is the 
most adequate method of determining sympathovagal 
balance [21]. According to tables with normal values, 
we divided our patients into sympathicus and parasym-
pathicus groups depending on predominance. Each group 
was further divided into two subgroups depending on 
whether marked or moderate dominance existed. Marked 
sympathetic dominance existed with high LF and low 
HF values, while sympathetic dominance was moderate 
if only LF values were high. Marked vagal dominance 
was diagnosed if high HF and low LF values were regis-
tered, while moderate dominance was associated with 
the elevation of HF values only. LF and HF analysis in 
normalized units enabled definite grouping of patients 
into sympathetic (47 patients: 29 male and 18 female) 
and parasympathetic groups (39 patients: 12 male and 
27 female). The main groups were further subdived into 
two subgroups with marked or moderate sympathetic 
or vagal predominance (Table 1).
Statistics
All data were analyzed using computer software package 
SPSS 11.05 system for Windows. Results were compared 
using paired samples by means of Student t-test or χ2-test and 
General Linear Model with repeated measures. Significance 
level was defined as p<0.05.
RESULTS
Clinical autonomic testing
Among the basic tests of parasympathetic function, Valsalva 
ratio decreased after three weeks of amlodipine therapy 
(before vs. after therapy: 1.1±0.7 vs. 0.9±0.7, p=0.034), heart 
rate response to deep breathing and heart rate response 
to standing (30:15) did not change significantly. Results 
of sympathetic tests did not differ significantly before vs. 
three weeks after amlodipine therapy (orthostatic hypo-
tension test: 0.6±0.6 vs.0.5±0.5 mm Hg, p=0.463; hand grip 
test: 1.6±0.6 vs. 1.7±0.5 mm Hg, p=0.471; mental stress test: 
0.4±0.5 vs. 0.4±0.5, p was non-significant; cold pressure 
test: 0.7±0.4 vs.0.5±0.5, p was non-significant).
Short-term ECG: P wave, PQ, QRS and QT analysis
Analysis of the QT, QTc interval, P wave and PQ interval 
duration in classic short time ECG recordings revealed that 
all parameters after amlodipine therapy became shorter 
(P wave: 108.66±20.2 vs. 107.97±17.3 ms; PQ interval 
158.32±23.6 vs. 156.92±20.0 ms; QT interval: 391.49±31.4 
vs. 388.31±35.0 ms and QTc interval: 426.94±25.3 vs. 
424.08±33.7 ms). QRS duration before and after amlo-
dipine therapy was stable (QRS: 92±21.0 vs. 92.7±3.6 ms). 
All results were without statistical significance.
Short-time HRV analysis
Short-time RR variability analysis did not establish statis-
tically significant changes for virtually all parameters, 
compared for periods before and after therapy. The param-
eters corresponding to the general status of the ANS, mean 
dRR, SD, MD, became significantly lower. Time domain 
parameters pNN50% and RMS, corresponding to vagal 
activity were also lower after three weeks of therapy with 
amlodipine. HF spectral component, as a reflection of 
vagal activity became also considerably lower with amlo-
dipine therapy, whereas LF, which reflected sympathetic 
function, reached higher values. Sympathovagal LF/HF 
ratio increased, indicating the dominance of the sympa-
thetic system after therapy.
Using nonlinear HRV analysis, we did not find signif-
icant changes after amlodipine therapy. There were no 
statistical significances related to the shape of Poincare 
plot before and after amlodipine therapy.
Table 1. Study population
Group
Number of patients
Male Female Total
Sympathetic I 16 (64.0%) 9 (36.0%) 25
Sympathetic II 13 (59.1%) 9 (40.9%) 22
Total 29 (61.7%) 18 (38.3%) 47
Parasympathetic I 6 (30.0%) 14 (70.0%) 20
Parasympathetic II 6 (31.6%) 13 (68.4%) 19
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Holter ECG: heart rate and rhythm analysis
Amlodipine therapy reduced average and maximal heart 
rate during 24-hour period, however, this reduction was 
not of statistical significance. Ventricular ectopic activity 
became less prominent after therapy where the number of 
VPB/h during the night was reduced, but not statistically 
significant. Also, the average number of SVPB was reduced.
Holter ECG: long-term heart rate  
variability analysis
Time domain parameters corresponding to the general 
status of the ANS (SDNN, SDNN index) and total power 
became significantly lower after amlodipine therapy. Time 
domain parameters corresponding to vagal activity, RMSSD 
and pNN50% also became lower. After amlodipine treat-
ment all spectral parameters, including total power (TP), 
ultra low frequency (ULF), very low frequency (VLF), LH, 
and HF significantly decreased as well as LF/HF ratio. LF 
corresponding to sympathetic activity decreased with statis-
tical significance (553.4±370.0 vs. 497.5±305.6, p=0.007).
Baroreflex sensitivity three weeks after  
amlodipine therapy
Parameters, Minimal Slope was lower and Maximal Slope 
higher after administration of the first dose of amlodipine 
(Table 2).
Parameter Baroreflex Efficacy Index (BEI) measured 
by sequence method and reflecting baroreflex sensitivity, 
was significantly lower after three weeks of amlodipine 
therapy (Table 3).
24-hour ambulatory blood pressure monitoring
The average systolic, diastolic and pulse pressure during 
the whole 24 hours, during daytime and night time were 
significantly lower after three weeks of amlodipine therapy. 
Early morning systolic and diastolic BP also became lower 
after amlodipine therapy. Amlodipine reduced the frequency 
of non-dipper episodes (night time systolic BP not at least 
10% lower of the average daytime systolic BP (Table 4).
Autonomic nervous system adjustment  
(ANSA) methodology
In the selected patient group with vagal dominance during 
resting state, LF, which is an index of sympathetic activity, 
showed a statistically significant increase in value after three 
weeks of amlodipine therapy (p=0.007, Table 5, Graph 1).
In the same patient group, HF, as an index of parasym-
pathetic activity, showed a statistically significant reduction 
in value after three weeks of amlodipine therapy (p=0.007, 
Table 6, Graph 2).
In the sympathicus group, there was a tendency towards 
a fall in sympathetic and a rise in vagal activity; however 
these observations were not of statistical significance.
Table 2. Beat-to-beat baroreflex sensitivity before vs. 30 minutes af-
ter the first dose of amlodipine
Baroreflex sensitivity Before After 30 
minutes p
Minimal slope  
(ms/mm Hg) 2.1±1.2 1.4±0.9 0.000
Maximal slope  
(ms/mm Hg) 33.7±22.5 45.8±30.8 0.000
Mean slope  
(ms/mm Hg) 11.6±7.4 10.4±5.6 NS
Baroreflex efficacy 
index (%) 93.6±37.9 94.2±35.6 NS
NS – non-significant
Table 3. Beat-to-beat baroreflex sensitivity before vs. three weeks 
after amlodipine therapy
Baroreflex sensitivity Before After 3 
weeks p
Minimal slope  
(ms/mm Hg) 7.6±4.9 6.1±4.6 NS
Maximal slope  
(ms/mm Hg) 33.0±26.9 29.6±23.8 NS
Mean slope  
(ms/mm Hg) 11.7±7.4 10.3±7.1 NS
Baroreflex efficacy 
index (%) 90.3±36.4 75.9±40.8 0.007
NS – non-significant
Table 4. 24-hour ambulatory blood pressure monitoring
Parameter
Before 
amlodipine 
therapy
After 
amlodipine 
therapy
p
24-hour 
average values 
(mm Hg)
SBP 134.98±14.9 127.52±11.9 0.001
DBP 84.33±9.8 80.23±7.9 0.001
PP 50.72±8.7 47.44±7.7 0.001
Average values  
during day  
(mm Hg)
SBP 136.77±19.8 131.31±11.9 0.003
DBP 86.40±10.2 82.49±8.2 0.008
PP 52.21± 9.5 48.52±8.6 0.016
Average values 
during night 
(mm Hg)
SBP 123.09±17.7 116.96±14.3 0.005
DBP 76.96±10.7 73.89±9.4 0.016
PP 45.88±10.0 42.93±8.5 0.024
Non-dipper* 
(%) 0.70±0.4 0.60±0.4 0.015
Early morning 
values  
(mm Hg)
SBP 135.41±30.9 129.17±18.2 0.048
DBP 88.95±15.6 84.09±11.0 0.041
SD of BP 
during day 
(BPV during 
day)
SBP 16.01±4.1 16.59±5.7 0.163
DBP 11.27±3.3 11.67±4.4 0.827
SD of BP  
during night  
(BPV during 
night)
SBP 11.6±6.5 11.2±5.1 0.703 
DBP 9.36±3.9 9.20±3.3 0.956
* frequency of SBP during night time that are not lower than 10% of the ave-
rage daytime SBP
SBP – systolic blood pressure; DBP – diastolic blood pressure; PP – puls pre-
ssure; SD – standard deviation; BP – blood pressure; BPV – blood pressure va-
riability
Table 5. Low frequency before vs. three weeks after amlodipine the-
rapy
Group Before After 3 
weeks p
Sympathetic 74.1±8.7 71.0±13.9 NS
Parasympathetic 49.3±16.2 59.3±17.1 0.007
NS – non-significantSERBIAN ARCHIVES OF MEDICINE 375
depend on the methodology used for the assessment of 
autonomic function. This study was aimed to fully eval-
uate the effects of amlodipine on autonomic function and 
related risk predictors, using a comprehensive protocol.
Cardiovascular Ewing’s reflex tests are simple and useful 
screening tests for the assessment of ANS, but with rela-
tively limited sensitivity compared to new methods based 
on the spectral analysis of biological signals, i.e. heart rate 
and blood pressure. In our study, Valsalva ratio, a marker 
of vagal activity became less positive. The results of other 
cardiovascular tests before vs. after three weeks of amlo-
dipine therapy did not change significantly. These data 
presumably reflect insufficiency of a standard cardiovas-
cular reflex test to detect discrete changes in autonomic 
function. Even Ewing in patients with diabetic neuropathy 
and normal results of cardiovascular tests found significant 
changes in spectral analysis of heart rate, implying rela-
tively limited sensitivity of standard tests [20].
HRV is widely used for the assessment of sympathovagal 
balance. In this study we performed time and frequency 
domain methods of short-term, long-term and beat-to-
beat analysis of HRV before and after amlodipine therapy. 
Short-term HRV analysis, three weeks after amlodipine 
therapy, revealed significantly lower values of all time 
domain parameters, as well as HF component, whereas LF 
component and LF/HF ratio were increased. At the same 
time, long-term HRV analysis revealed a reduction of all 
time domain parameters, reduction of all spectral compo-
nents with statistical significance for LF in concordance 
with decreased sympathetic activity. In long-term HRV 
analysis, LF/HF ratio was decreased, as well as mean and 
maximum heart rate during 24 hours were reduced, and the 
results were more suggestive of a shift towards vagal activity.
Rosinnen et al. [29] investigated the anti-ischemic affect 
of amlodipine in patients with coronary artery disease 
treated with beta blocker and also revealed unfavourable 
changes in the autonomic modulation of the heart induced 
by amlodipine (significant reduction of total variability 
and VLF component). Lefrandt et al. [24] also found in 
hypertensive patients that amlodipine induced a shift in 
sympathovagal balance, as measured by spectral analysis of 
HRV and plasma NE, toward sympathetic predominance 
compared with vagal predominance induced with vera-
pamil. Lindqist et al. [30] and Leenen et al. [31] confirmed 
that long-term calcium antagonists including amlodipine 
increased sympathetic nerve activity.
However, other authors demonstrated that amlodipine 
did not cause increment in sympathetic activity and that it 
did not cause significant changes either in time domain or 
spectral analysis of HRV [16]. Other studies also demon-
strated that amlodipine was quite neutral regarding auto-
nomic function [14, 32], whereas, nifedipine increased 
adrenergic, and verapamil vagal activity [24, 33]. Zaliunas et 
al. [16] found decreased LF without changes in HF of HRV 
spectrum in 30 patients with angina pectoris and hyper-
tension. According to our data we also found decreased LF 
as an index of sympathetic activity during 24-hour ECG 
ambulatory monitoring and could therefore conclude that 
amlodipine resulted in neutral or higher vagal activity 
following therapy.
Table 6. High frequency before vs. three weeks after amlodipine 
therapy
Group Before After 3 
weeks p
Sympathetic 25.8±8.7 28.9±13.9 NS
Parasympathetic 50.8±16.3 40.8±16.9 0.007
NS – non-significant
Graph 1. Low frequency before vs. three weeks after amlodipine 
therapy: increase of sympathetic activity (lower line) in vagal group
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Graph 2. High frequency before vs. three weeks after amlodipine 
therapy: decrease of vagal activity (upper line) in parasympathetic 
group
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DISCUSSION
The influence of calcium antagonists on the ANS differs 
between classes and depends on the pharmacodynamic 
profile of the specific drug [23-27]. Short-acting dihydro-
pyridine (DHP) calcium antagonists have been associated 
with increased morbidity and mortality in patients with 
hypertension and coronary artery disease due to reflex 
sympathetic activation in response to vasodilatation [27, 
28]. In contrast, long acting DHP and non-DHP act as 
vasodilators, but with less significant increase in sympa-
thetic activity. Data regarding the effects of amlodipine 
on sympathovagal balance are controversial and largely СРПСКИ АРХИВ ЗА ЦЕЛОКУПНО ЛЕКАРСТВО 376
In long-term analysis we found slight, but not statisti-
cally significant, prolongation of QT interval after three 
weeks of amlodipine, however, in short-term analysis, 
QT interval was shorter without statistical significance. 
Amlodipine non-significantly reduced the number of 
SVPB and VPB during the night, which could have been 
a potentially vagal effect.
We found that baroreflex sensitivity was temporarily 
increased after the first dose of amlodipine. With chronic 
amlodipine therapy baroreflex sensitivity became signifi-
cantly decreased compared to basal values. Siché et al. [15] 
in a smaller study, comprising 36 patients, did not find a 
statistical significance relation between amlodipine therapy 
and baroreflex sensitivity, whereas Lefrandt et al. [24], in a 
much larger study, found that chronic amlodipine therapy 
improved baroreflex sensitivity, although less effectively 
compared to verapamil.
By impendence cardiography we monitored the early 
effect of the first dose of amlodipine in 10 patients. The 
data obtained from haemodynamic assessment 30 minutes 
following the first dose of amlodipine, suggested a favour-
able influence of amlodipine on haemodynamic profile that 
could suggest safety of amlodipine in patients with heart 
failure, but these results were not statistically significant. 
Lindqvist et al. [30] also demonstrated increased cardiac 
output after amlodipine with increased adrenergic activity.
The effectiveness of amlodipine in BP reduction was 
confirmed in our study, concerning both systolic and 
diastolic BP. These data are in concordance with other 
studies [30, 34]. However, we found that the first dose of 
amlodipine slightly and transitorily increased BP, predom-
inantly diastolic BP. After three weeks of therapy, systolic 
BP, diastolic BP and pulse pressure decreased, though BPV 
during daily activities became more pronounced, but without 
statistical significance. According to previously published 
data, obtained in a lower number of patients, amlodipine 
decreased or did not affect BPV [34, 35].
By combining a number of methods we were able to 
confirm with great certainty the existence of a tendency 
towards sympathetic predominance following amlodipine 
therapy; the obtained results were not statistically signif-
icant, thereby developing a totally new approach in diag-
nosing autonomic dysfunction. We confirmed the hypoth-
esis that in patients with hypertension two types of auto-
nomic dysfunction existed concerning dominance. Following 
up the effects of amlodipine in the sympathetic and vagal 
groups, a statistically significant increase in sympathetic 
and reduction in vagal activity in the vagal group was 
evidenced. That is, in this patient group we confirmed that 
amlodipine proved efficacious in restoring the autonomic 
balance. In the sympathetic group a similar tendency was 
evidenced, but it was not of statistical significance.
By developing a totally new approach in diagnostics and 
treatment of autonomic disturbances, we also confirmed our 
initial hypothesis which stated that there were no general 
rules regarding the effects of the drug; its effects primary 
depended on basal sympathovagal balance in each indi-
vidual patient. The analysis of patients with hypertension 
enabled grouping into 2 groups and 2 subgroups, depending 
on the existence of strong or weak sympathetic or vagal 
dominance. This new diagnostic approach and treatment 
focused attention on the importance of restoring distorted 
autonomic balance in various diseases. Acceptance of 
this new approach brings into question the adequacy of 
prescribing individual drugs in individual patient groups. 
That is, the patient group in which a drug is most efficient 
will be determined.
CONCLUSION
Amlodipine has the most potent effect in correcting auto-
nomic disbalance in patients with increased vagal acitivity 
in resting state.SERBIAN ARCHIVES OF MEDICINE 377
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KRATAK SADRŽAJ
Uvod  Auto  nom  na mo  du  la  ci  ja funk  ci  ja kar  di  o  va  sku  lar  nog si­
ste  ma iz  me  we  na je kod oso  ba s esen  ci  jal  nom hi  per  ten  zi  jom.
Ciq ra  da  Ciq ra  da je bio da se is  pi  ta  ju ne  po  sred  ni i du­
go  roč  ni efek  ti amlo  di  pi  na na kar  di  o  va  sku  lar  nu auto  nom  nu 
funk  ci  ju i he  mo  di  nam  ski sta  tus bo  le  sni  ka sa bla  gom esen  ci­
jal  nom hi  per  ten  zi  jom.
Me  to  de ra  da  Is  tra  ži  va  we je ob  u  hva  ti  lo 90 bo  le  sni  ka (43 
mu  ška  ra  ca) sa bla  gom esen  ci  jal  nom hi  per  ten  zi  jom, pro  seč  ne 
sta  ro  sti od 52,12±10,7 go  di  na, ko  ji su is  pi  ti  va  ni ne  po  sred  no 
pre, 30 mi  nu  ta po  sle pr  ve do  ze od 5 mg oral  nog amlo  di  pi  na 
i na  kon tri ne  de  qe le  če  wa amlo  di  pi  nom. Pro  to  kol is  tra­
ži  va  wa je ob  u  hva  tao: ana  li  zu pro  men  qi  vo  sti krv  nog pri  ti­
ska i sr  ča  ne fre  kven  ci  je (engl. he art ra te va ri a bi lity – HRV), ana­
li  zu pro  me  na „udar­do­udar” po  mo  ću im  pe  dan  ci  je kar  di  o  gra­
fi  je, EKG sa soft  ve  rom za krat  ko  roč  nu HRV i ne  li  ne  ar  nu ana­
li  zu, 24­ča  sov  ni hol  ter EKG mo  ni  to  ring sa ana  li  zom QT in­
ter  va  la i HRV, 24­ča  sov  ni hol  ter pri  ti  ska sa pra  te  ćom ana­
li  zom pro  me  na si  stol  nog i di  ja  stol  nog krv  nog pri  ti  ska, te­
sto  ve za is  pi  ti  va  we kar  di  o  va  sku  lar  nog auto  nom  nog re  flek­
sa, test hlad  nom vo  dom i test men  tal  ne sti  mu  la  ci  je. Is  pi  ta­
ni  ci su svr  sta  ni u dve gru  pe, na  zva  ne „sim  pa  ti  kus” i „pa  ra­
sim  pa  ti  kus”, u za  vi  sno  sti od pre  do  mi  na  ci  je u krat  ko  roč  noj 
spek  tral  noj ana  li  zi sim  pa  to  va  gal  ne rav  no  te  že, u skla  du s 
vred  no  sti  ma ni  ske i vi  so  ke fre  kven  ci  je.
Re  zul  ta  ti  Za  be  le  že  no je zna  čaj  no sma  we  we vred  no  sti si­
stol  nog i di  ja  stol  nog krv  nog pri  ti  ska i puls  nog pri  ti  ska 
to  kom da  na, no  ći i ra  nih ju  tar  wih sa  ti. Sma  we  we bro  ja su­
pra  ven  tri  ku  lar  nih i ven  tri  ku  lar  nih ek  to  pič  nih uda  ra to­
kom no  ći je ta  ko  đe po  stig  nu  to pri  me  we  nom te  ra  pi  jom, ali 
ono  ni  je  bi  lo  sta  ti  stič  ki  zna  čaj  no.  Po  ve  ća  we  sim  pa  tič  ke 
ak  tiv  no  sti u ra  noj fa  zi le  če  wa amlo  di  pi  nom je ta  ko  đe bi­
lo bez sta  ti  stič  ke zna  čaj  no  sti, dok je odr  ža  va  we sim  pa  tič  ke 
pre  do  mi  na  ci  je po  sle ne  ko  li  ko ne  de  qa le  če  wa za  be  le  že  no 
na osno  vu re  zul  ta  ta krat  ko  roč  ne spek  tral  ne ana  li  ze HRV. Za­
be  le  že  no je i sma  we  we vred  no  sti svih vre  men  ski za  vi  snih 
pa  ra  me  ta  ra du  go  roč  ne HRV ana  li  ze, kao i spek  tral  nog pa  ra­
me  tra ni  ske fre  kven  ci  je. Amlo  di  pin je sma  wio ba  ro  re  flek­
snu sen  zi  tiv  nost na  kon tri ne  de  qe le  če  wa i do  veo do we  nog 
po  ve  ća  wa ne  po  sred  no na  kon pri  me  ne pr  ve te  ra  pij  ske do  ze.
Za  kqu  čak Re  zul  ta  ti ove stu  di  je po  ka  zu  ju da amlo  di  pin do  vo­
di do po  ma  ka sim  pa  to  va  gal  ne rav  no  te  že u smi  slu pre  do  mi­
na  ci  je sim  pa  ti  ku  sa, ali bez sta  ti  stič  ke zna  čaj  no  sti. U iza­
bra  noj gru  pi bo  le  sni  ka sa pre  do  mi  na  ci  jom va  gu  sa amlo  di­
pin po  ve  ća  va sim  pa  tič  ku, a sma  wu  je ak  tiv  nost va  gu  sa. Za  kqu­
ču  je se da amlo  di  pin ima naj  ve  ći uti  caj na mo  du  la  ci  ju funk­
ci  je auto  nom  nog ner  vnog si  ste  ma kod oso  ba sa pre  do  mi  na  ci­
jom va  gu  sa u sta  wu mi  ro  va  wa.
Kquč  ne re  či: amlo  di  pin; hi  per  ten  zi  ja; auto  nom  na funk  ci­
ja; pro  men  qi  vost sr  ča  ne fre  kven  ci  je; he  mo  di  na  mi  ka; sen  zi­
tiv  nost ba  ro  re  cep  to  ra
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